[go: up one dir, main page]

AR061155A1 - Preparaciones liofilizadas de pantoprazol sodico para inyeccion - Google Patents

Preparaciones liofilizadas de pantoprazol sodico para inyeccion

Info

Publication number
AR061155A1
AR061155A1 ARP070102372A ARP070102372A AR061155A1 AR 061155 A1 AR061155 A1 AR 061155A1 AR P070102372 A ARP070102372 A AR P070102372A AR P070102372 A ARP070102372 A AR P070102372A AR 061155 A1 AR061155 A1 AR 061155A1
Authority
AR
Argentina
Prior art keywords
sodium
injection
liofilized
pantoprazol
preparations
Prior art date
Application number
ARP070102372A
Other languages
English (en)
Inventor
Perez Sergio Lloret
Lopez Begona Duarte
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR061155A1 publication Critical patent/AR061155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una preparacion liofilizada para inyeccion, caracterizada porque comprende: i) entre aproximadamente 21 mg y aproximadamente 64 mg de pantoprazol sodico; y ii) entre aproximadamente 17 mg y aproximadamente 52 mg de citrato de sodio.
ARP070102372A 2006-06-01 2007-06-01 Preparaciones liofilizadas de pantoprazol sodico para inyeccion AR061155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80979106P 2006-06-01 2006-06-01

Publications (1)

Publication Number Publication Date
AR061155A1 true AR061155A1 (es) 2008-08-06

Family

ID=39149341

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102372A AR061155A1 (es) 2006-06-01 2007-06-01 Preparaciones liofilizadas de pantoprazol sodico para inyeccion

Country Status (2)

Country Link
AR (1) AR061155A1 (es)
WO (1) WO2009001163A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101961309B (zh) * 2010-09-15 2012-06-27 河南辅仁怀庆堂制药有限公司 注射用泮托拉唑钠配制工艺
CN102743351B (zh) * 2012-07-30 2013-05-29 刘时灵 泮托拉唑钠冻干药物组合物及其制备方法
BE1021311B1 (nl) * 2014-07-31 2015-10-28 Neogen N.V. Werkwijze voor het maken van een poedervormige protonpompremmer samenstelling, genoemde samenstelling en gebruik
CN113041226B (zh) * 2021-03-29 2022-10-14 海南锦瑞制药有限公司 一种注射用泮托拉唑钠的制备工艺
CN115444826B (zh) * 2022-10-14 2023-07-21 海南锦瑞制药有限公司 注射用泮托拉唑钠的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1235018A (zh) * 1999-04-22 1999-11-17 沈阳东宇药业有限公司 泮托拉唑钠冻干粉针剂及制备方法
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition

Also Published As

Publication number Publication date
WO2009001163A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
CY1116622T1 (el) Αντισωματα anti-cd22, τα ανοσοσυζευγματα τους και χρησεις αυτων
ECSP088463A (es) Antagonistas de activina-actriia y usos para promover el crecimiento óseo
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
AR056816A1 (es) Composicion con ácido docosapentenoico
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CY1117021T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
AR061348A1 (es) Preparados estables de laquinimod
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
ZA200803819B (en) Probiotic Enterococci for improved immunity
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
WO2007014391A3 (en) Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
AR061155A1 (es) Preparaciones liofilizadas de pantoprazol sodico para inyeccion
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2008128191A3 (en) Oral cephalotaxine dosage forms
MX2009003092A (es) Composiciones y metodos para suministro de farmaco dirigido a ph.

Legal Events

Date Code Title Description
FB Suspension of granting procedure